Amylyx Pharmaceuticals, Inc. (AMLX) AI Stock Analysis
AMLX AI stock analysis summary
AI ResearchAmylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases like ALS. After generating revenue of $380.8M and net income of $49.3M in FY2023, revenue contracted to $87.4M in FY2024 with a net loss of -$301.7M. Despite these commercial swings, the company maintains a robust balance sheet with $245.5M in net cash as of June 30, 2026.
- Market cap
- $3.31B
- Revenue (TTM)
- -$665,000
- P/E
- — fwd 2.8x
- 1Y return
- 73.6% S&P 500 16.8%
- Avg. target
- $43.00 63.2% vs last close
Bull case
- Shares have advanced 118.0% year-to-date and 73.6% over the past year, significantly outperforming broader market benchmarks.
- The company maintains a healthy liquidity profile, backed by $245.5M in net cash and a current ratio of 12.12 as of June 30, 2026.
- Wall Street analysts hold 11 Strong Buy ratings with an average price target of $43.00, implying 63.2% upside from the recent close.
Bear case
- Trailing twelve month revenue stands at -$665,000 following a 99.6% year-over-year quarterly revenue decline reported on June 30, 2026.
- In FY2024, the business consumed substantial capital, producing negative free cash flow of -$167.8M and a net loss of -$301.7M.
- Shareholder dilution has been substantial, with the company's share count increasing 101.4% over a 5-year period.
What Amylyx Pharmaceuticals does
Amylyx Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Founded in 2013, the company is centered on AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol designed to address the underlying mechanisms of ALS. In addition to ALS, Amylyx is exploring the therapeutic potential of AMX0035 in other neurodegenerative conditions to address broader challenges across neurology through clinical trials and strategic partnerships.
Growth and profitability
Amylyx experienced extreme top-line volatility over recent fiscal years. Revenue climbed from $22.2M in FY2022 to $380.8M in FY2023, generating positive net income of $49.3M and an operating margin of 10.2%. However, FY2024 revenue fell 77.1% to $87.4M, resulting in an operating margin of -360.2% and a net loss of -$301.7M. In the latest quarter ended June 30, 2026, quarterly revenue fell 99.6% year-over-year, leaving trailing twelve month revenue at -$665,000 and an EPS of -$1.41. R&D spending stood at $104.1M in FY2024, down from $128.2M in FY2023.
Balance sheet and cash flow
As of June 30, 2026, Amylyx held $250.8M in cash and short-term investments against $5.3M in total debt, yielding net cash of $245.5M. The company maintains solid liquidity, evidenced by a current ratio of 12.12 and a low debt-to-equity ratio of 0.02. In FY2024, operating cash flow was -$167.6M and free cash flow was -$167.8M. For FY2025, capital expenditures were modest at $138,000. Additionally, the company's share count expanded by 101.4% over a 5-year period.
Valuation and performance
AMLX shares closed at $26.34 on October 16, 2026, delivering a 1-year return of 73.6%, which outperformed the S&P 500 (SPY) return of 16.8%. The stock trades at a forward P/E of 2.8x, well below the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple of 0.7x also trades below the peer median of 4.1x, while its price-to-book ratio is elevated at 17.3x. Amylyx holds an enterprise value of $3.90B against a market capitalization of $3.31B.
What analysts expect
Wall Street sentiment includes 11 Strong Buy ratings, 1 Hold rating, and zero Sell ratings. The mean price target of $43.00 represents a potential upside of 63.2% compared to the last close of $26.34. Amylyx has beaten EPS estimates in 2 of the last 4 quarters. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.48 on $0 in revenue. For the following fiscal year, 8 analysts project revenue of $28.3M and an EPS of -$1.09. The next earnings date is November 5, 2026.
Key risks and what to watch
- Short interest represents 12.6% of float, indicating notable market skepticism regarding the company's pipeline and commercial prospects.
- Consensus analyst estimates forecast $0 in full-year revenue alongside an EPS loss of -$1.48 for the fiscal year ending December 31, 2026.
- Return on equity over the trailing twelve months stands at -74.7%, reflecting ongoing operating deficits.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AMLX AI stock analysis
This page is an AI-written research summary of Amylyx Pharmaceuticals, Inc. (AMLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AMLX income statement, AMLX balance sheet, AMLX key metrics, AMLX analyst forecast, AMLX chart. See the AMLX stock overview for the latest quote and news.
AMLX AI stock analysis FAQ
What was Amylyx's revenue performance over recent fiscal years?
In FY2023, Amylyx reported revenue of $380.8M, but sales fell 77.1% to $87.4M in FY2024. Over the trailing twelve months ended June 30, 2026, revenue was -$665,000.
Does Amylyx Pharmaceuticals pay a dividend?
Amylyx does not pay a dividend. Capital is focused on clinical pipeline activities, including $104.1M in R&D spending during FY2024.
How much cash and debt does Amylyx have?
As of June 30, 2026, the company held $250.8M in cash and short-term investments and $5.3M in total debt, resulting in net cash of $245.5M.
What are analysts forecasting for Amylyx's financial results?
Analysts estimate an EPS of -$1.48 on $0 in revenue for FY2026, followed by projected revenue of $28.3M and an EPS of -$1.09 in the next fiscal year.